^
Association details:
| Biomarker: | POLE mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PMC: A more precise classifier of POLE mutations to identify candidates for immune therapy.
Published date:
05/19/2021
Excerpt:
Four metastatic CRC patients with LOP POLE mutation were treated with immune therapy (nivolumab, or ipilimumab/nivolumab) in 2nd or 3rd line, all four achieved objective response and remain on therapy (mean time on treatment 15 mo).
DOI:
10.1200/JCO.2021.39.15_suppl.3548
